Sign Up to like & get recommendations! 0
Published in 2021 at "iScience"
DOI: 10.1016/j.isci.2021.102542
Abstract: Summary Ivacaftor (VX-770) was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulatory drug approved for the treatment of patients with cystic fibrosis. Electron cryomicroscopy (cryo-EM) studies of detergent-solubilized CFTR indicated that VX-770 bound to… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Critical Care Medicine"
DOI: 10.1097/ccm.0000000000002720
Abstract: Objectives: To determine the feasibility of using a cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770/Kalydeco, Vertex Pharmaceuticals, Boston, MA), as a therapeutic strategy for treating pulmonary edema. Design: Prospective laboratory animal investigation. Setting: Animal… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Current Opinion in Pulmonary Medicine"
DOI: 10.1097/mcp.0000000000000917
Abstract: Purpose of review The introduction of highly effective cystic fibrosis transmembrane conductance regulator modulators has resulted in a paradigm shift towards treating underlying cause of cystic fibrosis (CF) rather than the ensuing complications. In this… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Current opinion in organ transplantation"
DOI: 10.1097/mot.0000000000000975
Abstract: PURPOSE OF REVIEW Over the past decade, the development of highly effective cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators has dramatically ameliorated the manifestations of CF for most patients. Perhaps most importantly, CFTR modulators… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Internal Medicine Journal"
DOI: 10.1111/imj.15715
Abstract: A 17-year-old boy was assessed because of a 1-week history of thoracic pain without dyspnoea. The patient came from Pakistan 2 years earlier. He had a history of asthma and had delayed puberty. The family… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Nanomedicine"
DOI: 10.2217/nnm-2017-0115
Abstract: AIM Aim of the study was the development of ζ potential changing nanoparticles as gene delivery system for the cystic fibrosis transmembrane conductance regulator gene. METHODS Chitosan and carboxymethyl cellulose were modified with phosphotyrosine, a… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.937250
Abstract: Background and Aim Cystic fibrosis (CF) is a genetic disease that is difficult to treat and caused by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Small molecules have been used to treat… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Annals of Saudi Medicine"
DOI: 10.5144/0256-4947.2020.15
Abstract: ABSTRACT BACKGROUND: Cystic fibrosis (CF) occurs in populations in Saudi Arabia and the Gulf area. Approximately 2000 known variants have been identified for the CF transmembrane conductance regulator (CTFR) gene. Screening for ten of the… read more here.